AbbVie Announces Collaboration to Develop Monoclonal Antibody Therapy for COVID-19

A new collaboration to develop a novel antibody therapeutic to prevent and treat COVID-19 will focus on advancing a fully human, neutralizing antibody which targets the conserved domain of the spike protein of SARS-CoV-2.

AbbVie (North Chicago, IL, USA), University of Utrecht (Utrecht, the Netherlands), the Erasmus Medical Centre (Rotterdam, the Netherlands), and biotech company Harbor BioMed (Cambridge, MA, USA) have entered into a collaboration under which AbbVie will support UU, EMC and HBM through the preclinical activities, while simultaneously undertaking preparations for later stage preclinical and clinical development work. AbbVie will receive an option to exclusively license the antibody from the three parties for therapeutic clinical development and commercialization worldwide.

The fully human, neutralizing antibody 47D11 discovered by UU, EMC and HBM targets a conserved region of the virus' spike protein. In cell culture studies the antibody blocked infection by the SARS-CoV-2 and a second coronavirus SARS-CoV. The antibody is fully human, which is designed to facilitate its development and minimize immune-related side effects.

"Treatment and prevention of COVID-19 remains a critical global need. The antibody discovered by UU, EMC and Harbour BioMed is extremely promising based on the mechanism by which it targets the virus and on its developability as a fully human protein," said Tom Hudson, M.D., Senior Vice President, Research and Development and Chief Scientific Officer, AbbVie. "We look forward to working with this outstanding team to advance this antibody towards clinical trials."

"AbbVie is a global leader in developing innovative antiviral therapies," said Dr. Jingsong Wang, Founder, Chairman & Chief Executive Officer of HBM. "This collaboration will greatly accelerate our efforts to bring this antibody forward into clinical trials as quickly as possible and contribute a solution to this pandemic."

"The SARS-CoV-2 pandemic has highlighted the importance of understanding coronavirus biology," said Berend-Jan Bosch, PhD, Associate Professor, Research leader at UU. "The collaboration with AbbVie provides an excellent opportunity to translate our research into a clinical candidate with great potential for advancing the fight against this disease."

"The collaboration is an endorsement of our approach to fully human antibody discovery and development. Through this collaboration, we are well positioned to move rapidly towards clinical trials," said Frank Grosveld, PhD, Academy Professor of Cell Biology, EMC, Rotterdam and Founding Chief Scientific Officer at Harbour BioMed.

Related Links:
AbbVie
University of Utrecht
Erasmus Medical Centre
Harbor BioMed